๐Ÿ•ต๏ธ Regeneron Pharmaceuticals, Inc. ($REGN)

SEC insider & ownership activity, last 12 months ยท CIK 872589 ยท every row links its SEC filing

Over the last 12 months insiders sold $9.6M with no open-market buying against it. Christine A. Poon sold $4.3M (Oct). No red-flag 8-Ks in the window.

Aug 2025: net +$0 Sep 2025: net +$0 Oct 2025: net -$4.3M Nov 2025: net -$851K Dec 2025: net +$0 Jan 2026: net -$1.2M Mar 2026: net -$79K Mar 2026: net -$79K Apr 2026: net -$78K May 2026: net -$71K Jun 2026: net +$0 Jul 2026: net -$130K
Monthly net open-market insider flow, last 12 months (up = net buying)

Insider flow

0 buyers, $0 (0 lots) ยท 5 sellers, $9.6M (79 lots)

InsiderBuysBoughtSellsSoldLast
Christine A. Poon0โ€“ 6$4.3MOct 29, 2025
Pitofsky Jason0โ€“ 12$1.9MFeb 9, 2026
Bonnie L. Bassler0โ€“ 2$1.8MJan 7, 2026
Huda Y. Zoghbi0โ€“ 11$1.3MFeb 19, 2026
Arthur F. Ryan0โ€“ 48$435KJul 2, 2026

5%+ holders

HolderStakeClassScheduleEvent
Vanguard Capital Management 7.4% 13GApr 30, 2026 filing โ†—

Planned insider sales (Form 144)

SellerPlannedApprox. sale date
Arthur F. Ryan$250KJul 2, 2026 filing โ†—
Huda Y. Zoghbi$1.3MFeb 19, 2026 filing โ†—
Pitofsky Jason$1.6MFeb 9, 2026 filing โ†—
Arthur F. Ryan$314KFeb 9, 2026 filing โ†—
Bonnie L. Bassler$1.2MJan 7, 2026 filing โ†—
Bonnie L. Bassler$570KNov 20, 2025 filing โ†—
Jason Pitofsky$281KNov 7, 2025 filing โ†—
Christine Poon$4.2MOct 29, 2025 filing โ†—

Material events (8-K)

ItemEvent date
Earnings (2.02)Jul 30, 2026 filing โ†—
Financial Statements and Exhibits (9.01)Jul 30, 2026 filing โ†—
Earnings (2.02)Jul 6, 2026 filing โ†—
Shareholder vote (5.07)Jun 12, 2026 filing โ†—
Earnings (2.02)Apr 29, 2026 filing โ†—
Financial Statements and Exhibits (9.01)Apr 29, 2026 filing โ†—
Earnings (2.02)Apr 8, 2026 filing โ†—
Earnings (2.02)Jan 30, 2026 filing โ†—
Financial Statements and Exhibits (9.01)Jan 30, 2026 filing โ†—
Earnings (2.02)Jan 12, 2026 filing โ†—
Reg FD disclosure (7.01)Jan 12, 2026 filing โ†—
Financial Statements and Exhibits (9.01)Jan 12, 2026 filing โ†—
Earnings (2.02)Oct 28, 2025 filing โ†—
Financial Statements and Exhibits (9.01)Oct 28, 2025 filing โ†—
Earnings (2.02)Oct 6, 2025 filing โ†—
Earnings (2.02)Aug 1, 2025 filing โ†—
Financial Statements and Exhibits (9.01)Aug 1, 2025 filing โ†—